Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/12/2025

Cuvitru Therapy for CVID Patients

Diagnostic Criteria

  • Patients with confirmed CVID should have serum IgG level <450-500 mg/dL with IgA or IgM below the 5th percentile, impaired specific antibody responses to both protein and polysaccharide antigens, history of recurrent bacterial respiratory infections, and exclusion of secondary causes 1, 2
  • The American Academy of Allergy, Asthma, and Immunology emphasizes that patients must demonstrate significant reduction in ≥2 immunoglobulin isotypes (>50% below lower limit of normal), not simply borderline values 3

Standard Dosing Guidelines

  • The standard dosing for Cuvitru is 100-150 mg/kg/week subcutaneously (equivalent to 400-600 mg/kg/month) 1, 2, 4
  • The maximum documented dose in literature is up to 1.2 g/kg/month (300 mg/kg/week) for patients with established bronchiectasis 3, 5

Dosing Considerations

  • Any proposed dose significantly exceeding 300 mg/kg/week (1.2 g/kg/month) lacks evidence-based support and raises serious safety concerns 3
  • The Journal of Allergy and Clinical Immunology warns that the trend toward using larger, nonvalidated doses results in "significant and inappropriate expenditures" and potential harm 3

Target IgG Trough Levels

  • The minimum goal is 400-500 mg/dL to prevent serious bacterial infections 5
  • The individualized range is 500-1700 mg/dL based on clinical response (infection frequency/severity) 5
  • The American College of Chest Physicians emphasizes that the primary endpoint is clinical response (reduction in infection frequency and severity), not achieving a specific trough IgG level 5

Monitoring Requirements

  • IgG trough levels should be monitored every 6-12 months once stable (every 2 weeks during first 8 weeks if treatment-naïve) 4, 5, 6
  • Complete blood counts and serum chemistry should be monitored regularly 5
  • Clinical assessment of infection frequency, severity, and quality of life is necessary 5, 6

Multidisciplinary Care

  • All patients receiving immunoglobulin replacement should be under joint care of a clinical immunologist and respiratory specialist, as recommended by the British Thoracic Society 5

Adjunctive Therapies

  • Prophylactic antibiotics may be needed for breakthrough infections despite adequate IgG replacement 5
  • Prompt antibiotic treatment at onset of infections is necessary (patients should have antibiotics available at home) 6
  • Aggressive management of sinusitis and bronchitis is necessary to prevent progression to bronchiectasis 5

Cuvitru for CVID Patients

Rationale for Medical Necessity

  • Immunoglobulin replacement therapy is standard treatment for CVID to reduce serious bacterial infections and prevent irreversible organ damage, according to the American Academy of Allergy, Asthma, and Immunology 7
  • The efficacy of polyclonal human IgG for reducing serious bacterial infections in CVID patients is well established, as noted by the American College of Allergy, Asthma, and Immunology 7
  • Patients who experience adverse reactions to IVIG can successfully transition to subcutaneous immunoglobulin with improved tolerability, as recommended by the American Academy of Allergy, Asthma, and Immunology 8

Monitoring Requirements During Transition

  • Monitor IgG trough levels every 2 weeks during the first 8 weeks after transitioning to ensure adequate replacement, as suggested by the American College of Allergy, Asthma, and Immunology 7, 8
  • Once stable, monitor IgG trough levels every 6-12 months, and include blood cell counts and serum chemistry in regular monitoring, as recommended by the American Academy of Allergy, Asthma, and Immunology 7, 8

REFERENCES

4

CVID Diagnosis and Treatment Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

Medical Necessity of IVIG for Common Variable Immunodeficiency (CVID) [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6

Continued IVIG Therapy for CVID [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025